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Abstract
The main objective of this honor’s project is to encapsulate drugs with different molecular
weights inside of chitosan-heparin based nanoparticles (Cs-Hep NPs). Three different drugs with
low (NNC), medium (IFN-γ), and large (BSA) molecular weights were chosen in order to compare
all types of drugs and how they react with the nanoparticles. Analysis of particle size, zeta
potential, and a release study was performed. The release took place over a 168-hour time period
and liquid samples were taken throughout. The hypothesis was that the molecular weight of the
drug will correlate to the physical properties of the nanoparticles.
The results of the particle size analysis show that the largest particle size was determined
to be interferon gamma (IFN-γ, ~2500nm), NNC-042090 (NNC, ~450nm), Nanoparticles
(~350nm), and bovine serum albumin (BSA, ~50nm). The results of the zeta potential show that
the encapsulated particles have a higher electro potential than empty nanoparticles. NNC released
80% of the encapsulated drug, BSA released 70% of the encapsulated drug, while IFN-γ only
released about 50% of the encapsulated drug. Therefore, judging from these results, the hypothesis
partially holds true for all drugs.
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Executive Summary
Problem Statement

Drug delivery systems were first developed in the 1950s to help control the release of drugs
ingested by the human body. This allows for a constant release rate of the drug that would
otherwise be toxic with an uncontrolled release. Nanoparticles (NPs) are one of the best solutions
to this problem because of their great compatibility with the human body, the amount of flexibility
the nanoparticles present, and because of their ability to control the release of the drugs. Chitosan
and heparin were chosen to be the main components of the nanoparticles because of chitosan’s
ability to deliver drugs through various applications and also because of its positive surface charge.
Heparin was chosen because of its coagulative properties and because of its overall negative
surface charge. The synthesis of the nanoparticles involves an excess of heparin compared to the
chitosan; therefore, it can be assumed that the nanoparticles have a net negative surface charge.
Three different drugs with low, medium, and large molecular weights were chosen in order
to study the encapsulation of each drug in the nanoparticles. Using different molecular weights
will give a good understanding of all types of drugs and how they react with the nanoparticles. In
order to quantify the encapsulated nanoparticles, a particle size comparison, zeta potential
comparison, and a release study was performed. The particle size comparison determines the
average radius of each of the drugs that are encapsulated in the nanoparticles. The zeta potential
comparison shows the difference in the electro potential between the surface of the nanoparticles
and the surrounding fluid. This study helps show the stability and the degree of electrostatic
repulsion between the encapsulated nanoparticles. The release study was performed three times
for each of the three drugs in order to increase accuracy. Franz cells were placed inside of an
incubator at 37°C to carry out the release. The release took place over a 168-hour time period and
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liquid samples were taken every hour for the first eight hours, then every four hours until hour 32,
then every eight hours for until hour 56, and finally every twelve hours for until hour 72.
Results/Discussion
The results of the particle size analysis show that the largest particle size was determined
to be interferon gamma (IFN-γ, ~2500nm), NNC-042090 (NNC, ~450nm), NPs (~350nm), and
finally bovine serum albumin (BSA, ~50nm). These results are not what was expected from the
initial hypothesis because NNC has the lowest molecular weight but has the second highest particle
size and BSA has the highest molecular weight yet has the smallest particle size. These results
could be due to coagulation of the particles which cause improper readings and results during
analysis. The results of the zeta potential show that the encapsulated particles have a higher electro
potential than empty nanoparticles. These results were expected according to the initial hypothesis.
The results from the release study show that all the drugs followed a general logarithmic
trend for the release from the encapsulated nanoparticles. However, at the end of the 168-hour
trial, NNC released 80% of the encapsulated drug, BSA released 70% of the encapsulated drug,
while IFN-γ only released about 50% of the encapsulated drug. These results do not support the
initial hypothesis of the dependency on the molecular weight for the released amount and release
time.
Conclusions
The initial hypothesis for this study was that there was a constant relationship between the
release amount and release time of the encapsulated nanoparticles depending on the molecular
weight of the chosen drug. For some instances in this study the hypothesis holds true, however for
other instances it does not. For example, the hypothesis doesn’t hold true for the particle size
because the drug with the lowest molecular weight has the largest particle size while the largest
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molecular weight has the smallest particle size. Therefore, the particle size has an inverse
relationship to the molecular weight. This phenomenon could be caused by the clumping of the
smaller sized drugs during the analysis of the particle radius; therefore, obscuring the results. The
zeta potential experiment proved that the encapsulated nanoparticles have higher electro potential
than empty nanoparticles which was the expected outcome at the beginning of the project.
The release study showed an overall release of 80% for NNC particles, 70% for BSA
particles, and 50% for the IFN-γ particles. The results of the analysis of the IFN-γ samples should
be considered unreliable because of possible issues from the ELISA assay. Therefore, if only the
results from the BSA and NNC release studies are considered, the results align with the initial
hypothesis. This is because NNC has the lowest molecular weight and should therefore release
more volume quicker than a higher molecular weight drug. However, the release rate of the NNC
from the NPs were slower than expected which could be due to NPs clumping together during the
release. The results of the release studies were compared to standard curves for each of the drugs
which can be seen in Figures 4-9. These results do not fully correlate to any trend with the
molecular weights of the drugs. Therefore, more analysis should be considered.
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Introduction
The modern-day drug delivery systems are only 60 years and have be developed and
advanced for the human body.[1] However, there are still multiple discoveries to be made to
improve the drug delivery inside the human body, specifically in the CNS (central nervous
system). The main objective of this honor’s project is to encapsulate drugs with different molecular
weights inside of chitosan-heparin based nanoparticles (Cs-Hep NPs) that are beneficial for
various applications in the human body. For example, healing and regeneration in the CNS is one
such application. The characterization of Cs-Hep NPs such as particle size, zeta potential, etc. were
conducted when these drugs/proteins are encapsulated. Multiple release studies were performed to
record the rate at which the drugs/proteins will be released from the nanoparticles. After the testing
is complete, all the data were assessed in order to compare and summarize the differences between
the drugs’/proteins’ release rate from the NPs with respect to molecular weight. The two specific
objectives of this project as described below:
1. Synthesis and characterization of the drug encapsulated Cs-Hep NPs
The first step for completing this project was to synthesize and characterize the Cs-Hep NPs
system. The lab had already synthesized these nanoparticles successfully in previous procedures.[2]
Next, the encapsulation process of the drugs was completed. Three different drugs were used
which were, interferon-γ (IFN-γ), Bovine Serum Albumin (BSA), and NNC-042090. The main
hypothesis for this objective is that synthesized Cs-Hep NPs have the capability to encapsulate the
previously mentioned drug molecules. Part of this process included synthesis of NPs,
encapsulation of NPs, separation of NPs by sequential centrifugation, and freeze-drying the
solution of the drug/protein encapsulated NPs. This produced a dry sample that made it easy to
handle and test.
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2. The release study of the drug encapsulated Cs-Hep NPs
The synthesized system was assessed for a drug/protein release study using standard release
protocol available in the lab. The drug samples from the release study were analyzed by using an
UV spectrometer and ELISA (enzyme-linked immunosorbent assay) depending upon the
drug/protein. The samples were drawn after an equal time interval to analyze the stepwise release.
The hypothesis for this objective is that the whole system will provide controlled drug release.
Three different drugs were chosen to be analyzed during this experiment: bovine serum
albumin (BSA), interferon gamma (IFN-γ), and NNC (NNC 05-2090). These three drugs were
chosen because of their wide range in molecular weights; NNC having the lowest molecular
weight, IFN-γ having the next largest, and BSA having the largest overall molecular weight.
During this study, the correlation between the different molecular weights were assessed with the
particle sizes, the zeta potentials, and the release study results. The hypothesis was that the trends
will follow the correlation between the different molecular weights.
Background
The beginning of the modern-day drug delivery systems began in 1950 and have been very
successful for creating several oral and transdermal controlled chemical release mechanisms.[3]
However, as of late (1980s-present), there have been no successful clinical trials for advanced
chemical release systems. These failures are caused by two different types of barriers within the
human body, biological barriers, and physicochemical barriers.[1] The physical-chemical barriers
have been the poor water solubility of the drugs, the large molecular weight of the drugs, and the
difficulty of controlling the drug release kinetics. The main biological barrier is getting the drug
to be dispersed throughout the entire body instead of being localized around the release center.
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Better control over the dispersion of the drug will give more control of the dosage and
concentrations of drugs being delivered.[1]
Chitosan, which is a biodegradable, biocompatible polymer, is considered safe for wound
dressing applications and human consumption. Chitosan-based nanoparticles are being heavily
investigated because of its ability to deliver drugs through various applications and because of its
chemical functional groups that can be easily modified. Another benefit of the chitosan polymer
is that nanoparticles that are formed by chitosan typically had a positive surface charge.[4]
Heparin is a naturally occurring compound produced by the liver which has become the
most common anticoagulant drug used in the world today. Heparin is paired with the chitosan to
be the main ingredients in the synthesis of the nanoparticles in this experiment. The heparin is used
in an excess quantity than chitosan and hence it is assumed that the NPs surface has a negative
charge.[5]
Experimental Methods
Materials
Chitosan (Mycodev, 90 kDa, 90% DDA), heparin sodium salt from porcine intestinal
mucosa (Sigma), glacial acetic acid (Fisher Scientific), sodium acetate trihydrate, nanowater was
used to synthesize NPs. Drug NNC04-2090 (Torcis Bioscience) and proteins, BSA and IFN- ɣ are
used for the experiments. Pierce 660 nm Protein Assay Reagent (450mL) and pre-diluted protein
assay standard sets were used to analyze the BSA and NNC from the release study. ELISA kit
(Peprotech) is used to analyze IFN-ɣ.
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Methods
The procedure for this project was broken down into three main parts. First, it was
necessary to synthesize the nanoparticles by following a procedure previously established by the
senior student in the Leipzig Bioengineering lab.[2] The procedure entailed creating an acetate
buffer (pH~5) and then mixing the buffer with chitosan and heparin. The chitosan mixture should
have a concentration of 0.90 mg/mL and the heparin mixture should have a concentration of 0.95
mg/mL. Next, the heparin and chitosan were mixed together at a ratio of 15 mL heparin to 5 mL
chitosan. The mixture was then mixed at 800 RPM for 3 hours and left to sit overnight. The solution
was then decanted, placed into a 50 mL C-tube, and centrifuged at 4300 RPM for 20 minutes with
rotor JS-5.3. After the solution was centrifuged, the top 15 mL of the supernatant was removed
and replaced by 15 mL of filtered nanowater. The solution was vortexed for 5 minutes and then
placed back into rotor JS-5.3. The C-tubes with solution were centrifuged for 15 minutes at 4300
RPM. The C-tubes were removed from the centrifuge and 15 mL of the supernatant was removed
from the tubes. The mixture was vortexed for 5 minutes and was finally stored in a -20°C freezer.
Next, the encapsulation of the drugs in the nanoparticles took place. The diluted drug (in
nanowater) was then added to the nanoparticle solution by using a syringe while mixing the
nanoparticle solution at 800 RPM. This ensured maximum encapsulation of the drug in the
nanoparticles. After being mixed for 1 hour, the solution was transferred to a 50 mL C-tube. The
tube was then transferred to the centrifuge with the JA-25.5 rotor. The solution was centrifuged at
8612 RPM (9000 x g) for 15 minutes. Then, the C-tube was taken out of the centrifuge, and 15 mL
of the top supernatant was removed and replaced by 15 mL of filtered nanowater and then vortexed
for 5 minutes. The C-tube was placed back into the centrifuge and ran again at 8612 RPM for 15
minutes. After complete, the top 15 mL of supernatant was removed and then the remaining
10

solution was vortexed and then stored in a -80°C freezer to be prepared for freeze drying. Freeze
drying occurred once the solution was completely frozen.
The final part of the procedure consisted of a time release study of the three different types
of drugs in the nanoparticle system. The release study took place in a Franz cell and was conducted
over the time period of a week. Below, in Figure 1: Setup of a Franz Cell, the setup of the Franz
cell for the release study is shown.

Figure 1: Setup of a Franz Cell
The receptor chamber was first filled with 15 mL of Phosphate Buffered Saline (PBS) in
order to control the pH of the solution and also act as a drying agent for the proteins to encourage
denaturation. Next, the stir-bar was added along with the membrane, flat flange joint, and a clamp
to secure the connection between the donor and receptor chambers. Once the connection was
secured, 3.5 mL of the drug/PBS mixture was added to the donor chamber. Nine total release
studies (3 drugs x 3 runs) were performed, which included three studies of each encapsulated drug
11

and a standard study for each nonencapsulated drug. For the encapsulated drug samples, the ratio
of PBS to the encapsulated drug was 1 mL to 2.5mL in the donor chamber.
To start the release study, the Franz cells were placed onto a stirring plate in an incubator
in order to simulate internal human body conditions. The stirring plate was set to 200 RPM in
order to keep the solution moving and to prevent stagnation in the receptor chamber. A sample
(~0.2mL) was taken from the Franz cell through the sampling port every hour, for eight hours,
then every four hours for 32 hours, then every eight hours for 56 hours, and then finally every
twelve hours for 72 hours. After the sample was taken, the Franz cell was replenished with an
equal amount of fresh PBS that was added through the sampling port. Samples were taken with
needles attached to 1 mL syringes. Each sample was clearly labeled and stored in 2 mL tubes which
were placed in a -20°C freezer until analyzed.
Analysis of the BSA samples collected after the release study was conducted using Pierce
660 nm assay (the protocol used was published by Thermo Scientific).[6] While the NNC samples
were analyzed using the UV spectrometer at 290 nm to determine the concentration of each drug
as time increased through each sample. First, the standard curve was determined using the known
concentration of the drug/protein using the same respective protocols.
To analyze the IFN-γ samples, an ELISA protocol was followed which was published by
PeproTech.[7] After all data was collected, it was analyzed and summarized.
Data and Results
The figures below show the results of the experiments performed throughout this study.
Figure 2 relates to the particle size of the NPs. Error bars have been added to the figure to show
the variance of all samples tested. The letters A, B, and C represent the difference between the
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samples. If they are the same letters then there is no significance between the groups, and if the
letters are different then the groups are significantly different. The particle size was calculated
for the empty nanoparticles, the BSA encapsulated NPs, the NNC encapsulated NPs, and the
IFN-γ encapsulated NPs. The particle diameter (nm) is the parameter being compared in Figure
2.
Figure 3 relates to the zeta potential of the different types of NPs. The zeta potential was
used to express the electro-kinetic charge that developed between the surface of the nanoparticles
and the liquid surrounding the nanoparticle.[8] Error bars have been added to the figure to show
the variance of all samples tested for zeta potential. The letters A, B, and C represent the
difference between the samples. If they are the same letters then there is no significance between
the groups, and if the letters are different then the groups are significantly different. Figure 3
shows the zeta potential in millivolts for each encapsulated nanoparticle.
Figures 4, 5 relate to the BSA trials. Figure 4 shows the standard curve of the BSA
encapsulated NPs. Figure 4 was used as a reference for the different absorbance values captured
from the release study when being evaluated. Figure 5 shows the data collected from the BSA
release study trials. Error bars are included to show the amount of variation between the data
collected and the standard curve from Figure 4. Figure 4 shows the percentage of cumulative
release of the BSA per hour.
Figures 6, 7 relate to the NNC trials. Figure 6 shows the standard curve of the NNC
encapsulated NPs. Figure 6 was used as a reference for the different absorbance values captured
from the release study when being evaluated. Figure 7 shows the data collected from the NNC
release study trials. Error bars are included to show the amount of variation between the data
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collected and the standard curve from Figure 6. Figure 7 shows the percentage of cumulative
release of the NNC per hour.
Figures 8, 9 relate to the IFN-γ trials. Figure 8 shows the standard curve of the IFN-γ
encapsulated NPs. Figure 8 was used as a reference for the different absorbance values captured
from the release study when being evaluated. Figure 9 shows the data collected from the IFN-γ
release study trials. Error bars are included to show the amount of variation between the data
collected and the standard curve from Figure 8. Figure 9 shows the percentage of cumulative
release of the IFN-γ per hour.

Figure 2: Particle size of the nanoparticles only (NPs) and drug/protein encapsulated NPs.
Results are presented as a mean of 3 different trials with error bars shown as standard error. The
letters A, B, and C relates data within 20% of each other.

14

Figure 3: Zeta potential of the nanoparticles only (NPs) and drug/protein encapsulated NPs.
Results are presented as a mean of 3 different trials with error bars shown as standard error. The
letters A and B relates data within 20% of each other.

Figure 4: Standard curve BSA at different concentrations
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Figure 5: Release study of BSA from NPs, results are presented as a mean of 3 different trials
with error bar shown as standard error

Figure 6: Standard curve of NNC 05-2090 at various concentrations
16

Figure 7: Release study of NNC 05-2090 from NPs, results are presented as a mean of 3 different
trials with error bar shown as standard error

Figure 8: Standard curve of IFN-γ at various concentrations
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Figure 9: Release study of IFN-γ from NPs, results are presented as a mean of 3 different trials.
Error bars were not able to be added because of the inconsistency of the standard curve of IFN-γ

Discussion/Analysis
The initial hypothesis for this study was that NPs have a capability to encapsulate
drug/protein molecules within them. Also, it was hypothesized that these encapsulated
drug/proteins will be released controlled over the period of time depending upon the particle size.
We were anticipating the particle of NNC encapsulated drugs would be smaller than IFN-ϒ and
BSA encapsulated NPs would have been the largest since molecular size of BSA is largest then
IFN-ϒ and then drug molecule NNC. The exact molecular weights can be found in the Appendix
in Table 1. Portions of this hypothesis were found to be correct but were not as consistent as
previously hypothesized.
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The results from the particle sizing can be seen in Figure 2. The expected results were that
the NPs would be have the smallest radius, then the NNC encapsulated particles, the IFN-γ
encapsulated particles, and finally the BSA encapsulated particles. The actual results show that the
smallest particles are the BSA encapsulated particles, then the empty nanoparticles, the NNC
particles and finally the IFN-γ particles. One explanation for why this phenomenon could’ve
happened are because the nanoparticles stuck together during the analysis. This would result in a
skewing of the results greatly and produce the results collected. In order to analyze with more
accurate results, a procedure for separating each nanoparticle must be followed to ensure
measurement of each individual nanoparticle instead of nanoparticle clusters or coagulations.
The results of the zeta potential can be seen in Figure 3. The results from this experiment
generally follow the hypothesis for this study. The empty nanoparticles show the lowest zeta
potential while the other three drugs show roughly the same values for their zeta potential. These
results show that there are negligible differences between the zeta potentials between the different
types of drugs. However, there is a significant difference between the zeta potential values of
empty nanoparticles versus encapsulated nanoparticles.
A standard curve was constructed for each of the three drugs involved in the study. The
results can be seen in Figures 4, 6, 8. The BSA and NNC standard curves produced useful results;
however, the IFN-γ curve produced inconclusive and varied information. An explanation for the
inconclusive results could be poor cleaning during the ELISA protocol which could result in the
variating results. Another possibility could be the improper formulation of the rinsing and cleaning
agents for the ELISA protocol. Or bad reagent (too old) was supplied for the ELISA procedure.
Each possibility could greatly affect and alter the results of the IFN-γ samples.
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The standard curves for BSA and NNC showed a general linear trend throughout the graph.
BSA shows a R2 value of 0.9065 and the NNC shows a R2 value of 0.7258. Both are reasonable
values to assume a linear trend. These standard curves were the basis of computing concentration
of release samples drawn at different time points.
The average results from the three release studies are shown in Figures 5, 7, 9. The release
study for BSA resulted in an overall release of about 70% of the encapsulated drug over the 168hour testing period. The release rate follows a general logarithmic trend, which meant higher initial
release and slower release over the rest of the experiment. The release study for NNC resulted in
an overall release of about 80% of the encapsulated drug over the 168-hour testing period. Since
the NNC molecules are very tiny, burst releases were expected in the first half of the trials;
however, none of these properties were observed from the collected data. The release rate also
follows a logarithmic trend, similar to the BSA trend. The release study for IFN-γ resulted in an
overall release of only 50% of the encapsulated drug over the 168-hour testing period. These results
seem skewed, since IFN-γ has the lowest molecular weight of any of the drugs, therefore it should
have the most drug released. However, the trend of the release rate follows the same logarithmic
trend as the other two drugs. Some error likely occurred with this assay during analysis and
unfortunately could not be retested because of time constraints.
Error bars were used in the graphs in order to show the variance between each of the three
trials for each of the drugs and each of the standards that were calculated. Due to a lack of time,
no additional analysis or trials were able to be completed to verify/expand on the results gathered
in this report. To improve accuracy in the future, additional analysis and trials should be
considered.
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Conclusions/Recommendations
The initial hypothesis for this study was that there was a constant relationship between the
release amount and release time of the encapsulated nanoparticles depending on the drug of
choice’s molecular weight. This theory was not constant for the whole project. As seen in Figure
2, the particle size of each encapsulated drug does not correlate to the molecular weight of the
drugs. This is believed to be inconsistent because of the common case of nanoparticles sticking
together, causing improper measurements of particle radii. The results of the zeta potential for
different drugs can be seen in Figure 3. The zeta potential followed the trend of the hypothesis
and correlates from the lowest molecular weight drug to the highest molecular weight drug.
The data from the release studies were compared to standard curves for each drug. These
results can be seen in Figures 4-9. Error bars are shown on the BSA and NNC release study graphs
to show the variance from the standard curves. The BSA sample released 70% of its drug in the
168-hour time period and the NNC sample released around 80% of its drug in the same amount of
time. These results were expected because NNC has the lowest molecular weight; however, the
rate at which the NNC was released was a lot slower than anticipated. The IFN-γ release studies
were not able to be compared to a standard because of how poorly the standard curve turned out
from the ELISA protocol. Therefore, no definitive information could be obtained from this study.
Recommendations for this project include using fresh and sealed assay agent for the ELISA
protocol in order to ensure correct analyzation of IFN-γ. For future experiments that are similar to
this one, a different selection of drugs could be beneficial. To ensure the accuracy of measuring
particle size, the nanoparticles should be vortexed intensely in order to attempt to break up clusters
of nanoparticles before analysis. Also, having more than three Franz cells when testing the release
studies would help ensure accuracy and would save a lot of time.
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Appendices
Table 1: Molecular weights of all three drugs used in the experiments
Drug Molecular Weights
BSA
IFN-γ
Bovine serum albumin Interferon Gamma
66.5 kDa
16.9 kDa
Highest
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NNC
NNC 05-2090
451 g/mol
Lowest

